Trump’s Tariffs, NIH Cuts, FDA Approvals & SBIR Debate | This Week in Making Medicine
In this week’s episode, John Stanford breaks down the latest headlines across Washington, the FDA, NIH, and industry. We cover the Trump cabinet’s tariff-drug pricing push, BARDA’s funding of vaccine research following recent pivots away from mRNA vaccines, a hopeful return of biotech IPOs, and NIH program cuts. Plus, we debut the FDA Approvals Corner celebrating new medicines reaching patients, and spotlight the looming September deadline for the SBIR and STTR programs.
What do you think about tariffs being tied to drug pricing?
Should Congress extend SBIR funding as-is, or rethink the…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.